This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Herzyk, D J Articles by Wier, P J Search for Related Content PubMed PubMed Citation Articles by Herzyk, D J Articles by Wier, P J Social Bookmarking                         What's this?

Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero

UE0360, Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, P.O. Box 1539, King of Prussia, Pennsylvania 19406, USA; danuta.j.herzyk{at}gsk.com

P J Bugelski

T K Hart

P J Wier

Departments of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA

Keliximab is a human-cynomolgus monkey chimeric (Primatized) monoclonal antibody with specificity for human and chimpanzee CD4. As the preclinical safety assessment of biopharmaceuticals requires evaluation in pharmacologically responsive species, comprehensive toxicology studies, including reproductive toxicity, of this antibody were conducted in a human CD4 transgenic mouse model. The reproductive toxicology studies included a preand postnatal development study that incorporated immunotoxicological evaluation of offspring (F1) mice. The potential effects of exposure to treating maternal mice (F0) with keliximab during pregnancy and lactation on offspring viability, physical growth, neurobehavioral development, reproductive function, lymphoid tissue morphological structure, lymphocyte subsets and host resistance to Candida albicans infection were assessed. The results showed no impairment of these functions. The use of F1 transgenic mice in study with keliximab provides an example of a novel practical approach to assess developmental immunotoxicity within a study of preand postnatal development designed in accordance with ICH Guidelines.

Key Words: anti-CD4 antibody • C. albicans infection • lymphoid tissues • offspring • transgenic mice

Human & Experimental Toxicology, Vol. 21, No. 9-10, 507-512 (2002)
DOI: 10.1191/0960327102ht289oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. L. Bussiere, P. Martin, M. Horner, J. Couch, M. Flaherty, L. Andrews, J. Beyer, and C. Horvath Alternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals International Journal of Toxicology, May 1, 2009; 28(3): 230 - 253. [Abstract] [Full Text] [PDF]